ProMIS Neurosciences Announces Fiscal Year 2021 Results
TORONTO, Ontario and CAMBRIDGE, Massachusetts , March 17, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS”...
TORONTO, Ontario and CAMBRIDGE, Massachusetts , March 17, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS”...
NEW YORK and VIENNA, Austria, March 17, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing...
Full-Year 2021 Total Revenues of $23.8 Million; Product Revenues Up 46% Positive Top-Line Data for EscharEx Phase 2 Clinical Trial,...
CAMBRIDGE, Mass., March 17, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines...
Over $140M in capital raised in initial public offering in 2021; Cash runway through first half 2024 Advanced IK-930, lead...
Harmony remains ongoing, with OLE study intended to gain insights into long-term exposure to ADP101 in qualifying patientsMENLO PARK, Calif.,...
-FYARRO™ approved November 22, 2021 and launched February 23, 2022- -FYARRO added to NCCN® Guidelines as the only preferred therapy...
FDA review of NDA for FT218 is ongoing; commercial and launch preparations on-track to support potential commercial launchExpanded the robust portfolio of...
CAMBRIDGE, Mass., March 17, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), a biopharmaceutical company focused on developing...
GATINEAU, Québec, March 17, 2022 (GLOBE NEWSWIRE) -- HEXO Corp (“HEXO”, or the “Company”) (TSX: HEXO; NASDAQ: HEXO) plans to...
– DesCAARTes™ trial progressing in cohort A5 with presentation of DSG3-CAART clinical and translational data from cohorts A3 and A4...
London Clinic Will Begin Delivering Ketamine-Assisted Therapy for Addiction & Mental HealthThird Location Adds to Two Existing Operatons in Bristol...
Nym’s Coding Engine Automates Revenue Cycle Management for Level 1 Pediatric Trauma Center, Bringing Greater Accuracy, Efficiency and Speed to...
Transformational year highlighted by global revenue of $475 million and 36% growth SAN FRANCISCO--(BUSINESS WIRE)--Real Chemistry, a global health innovation...
First three patients underwent successful implantation and clinical utilization of PortIO as part of a first-in-human study in Colombia, South...
The collaboration focuses on SphingoTec's near patient diagnostic solution for critical care settings.Rivaara gains exclusive rights to market and distribute...
STOCKHOLM, SWEDEN / ACCESSWIRE / March 17, 2022 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6)AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical...
STOCKHOLM, SWEDEN / ACCESSWIRE / March 17, 2022 / Promore Pharma (STO:PROMO) (FRA:8T0)STOCKHOLM, 17 March 2022 - Promore Pharma AB,...
STOCKHOLM, SWEDEN / ACCESSWIRE / March 17, 2022 / iZafe Group (STO:IZAFE-B)iZafe Group (publ.) hereby announces that the partner Zafe...
Study further highlights potential of RaDaR to stratify patients and improve treatment outcomesFT. MYERS, FL / ACCESSWIRE / March 17,...